Abreos Biosciences is planning to develop a novel therapeutic for treatment of multiple sclerosis, a chronic neurological disease. Our approach will be to study a well characterized biologic in a new indication facilitated by our platform for precision personalized dosing.

 

This approach will significantly de-risk the development pathway and create a unique competitive entry in a disease with continuing high levels of unmet need. 

 

If you are interested in more information or to participate, please email Michael Williams at